Background：Oleclumab as known as MEDI9447 is a human monoclonal antibody mAb being investigated for the treatment of various types of cancer like Solid Tumors, Pancreatic and Colorectal cancer. It is a monoclonal antibody against the ectoenzyme CD73 cluster of differentiation 73, also known as 5'-nucleotidase 5'-NT; ecto-5'-nucleotidase; NT5E with potential antineoplastic activity. This drug was developed by MedImmune, LLC and AstraZeneca plc. In contrast with many other cancer immunotherapy agents such as checkpoint inhibitors or T cell agonists, MEDI9447 drives changes in both myeloid and lymphoid infiltrating leukocyte populations within the tumor microenvironment. Changes include significant increases in CD8 effector cells and activated macrophages, as well as a reduction in the proportions of myeloid-derived suppressor cells MDSC and regulatory T lymphocytes. Furthermore, these changes correlate directly with responder and non-responder subpopulations within the arms of animal studies using syngeneic tumors. Data showing additive activity between MEDI9447 and other immune-mediated therapy antibodies demonstrates the importance of relieving adenosine-mediated immunosuppression within tumors.
